Cochrane identifies priority topics for review

We are pleased to announce the publication of the first Cochrane-wide Priority Review List. The creation of this list represents the achievement of a key milestone for Target 1.1 Prioritisation, a part of Cochrane’s Strategy to 2020. In this target we set out to identify about 200 Cochrane reviews, either new titles or reviews requiring updates, that best meet the needs of healthcare and health policy decision makers.

Cochrane Review compares two drugs used for treatment of macular degeneration

Cochrane Review shows how a cheaper alternative to licensed drug for treating eye disease has similar side effects

Neovascular macular degeneration is a progressive and chronic disease of the eye, and a leading cause of blindness in older people globally.

About one in 10 people with macular degeneration suffers legal blindness.

Subscribe to Cochrane RSS